Search Results for: Can-Fite

By Jewish Business News On Monday, May 4th, 2015
0 Comments

Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.

– – Israel’s Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, More...

By Jewish Business News Correspondent On Monday, March 23rd, 2015
1 Comment

Cipher Pharmaceuticals acquires Canadian rights from Israeli Can-Fite for psoriasis, rheumatoid arthritis treatment

  Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Israeli Can-Fite Biopharma (NYSE MKT: CANF) (TASE: More...

By Jewish Business News On Wednesday, March 18th, 2015
0 Comments

Can-Fite Developed Test to Predict Patients’ Response to Drugs

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the development of a commercial predictive More...

By Jewish Business News On Tuesday, February 17th, 2015
0 Comments

Can-Fite Receives Notice of Allowance in US for Psoriasis Patent

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, announced that it has received a Notice of Allowance More...

Can-Fite is part of Israel startup nation
By Jewish Business News Correspondent On Tuesday, January 27th, 2015
0 Comments

Can-Fite’s new Drug Fights Diabetes-Related Erectile Dysfunction

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, reported it has received positive data regarding its More...

By Gil Tanenbaum On Tuesday, December 30th, 2014
0 Comments

Israel’s Can-Fite BioPharma Moves Forward with Rheumatoid Arthritis Drug

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, has completed the Design of the Rheumatoid Arthritis More...

By Gil Tanenbaum On Monday, December 22nd, 2014
0 Comments

Can-Fite Treats First Patient with New Cancer Drug

Israel’s Can-Fite BioPharma Ltd., a biotechnology company which develops proprietary small molecule drugs for treating cancer and inflammatory diseases, treated the first patient with its CF 102 in a Phase More...

Can-Fite is part of Israel startup nation
By Gil Tanenbaum On Wednesday, October 1st, 2014
0 Comments

Can-Fite BioPharma Liver Drug Gets US Patent

Israel’s Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, has received a patent in the US for its drug More...

Can-Fite BioPharma
By Jewish Business News Correspondent On Monday, December 30th, 2013
0 Comments

Can-Fite’s CF101 Trial In Dry Eye Syndrome Fails To Meet Endpoints

– Can-Fite CEO Pnina Fishman: The fact that the safety profile of CF101 remains high is encouraging. – CEO Pnina Fishman / Ilan Besor – Can-Fite BioPharma Ltd. ( CANF ) announced today that the More...

By Jewish Business News Correspondent On Monday, December 23rd, 2013
1 Comment

Can-Fite Reports Positive Rheumatoid Arthritis Treatment Results

– The 12-week Phase IIb study involving 79 patients with active rheumatoid arthritis met all its primary efficacy endpoints. – Can-Fite BioPharma Ltd. (TASE:CFBI; Bulletin Board:CANFY)  reports positive More...

Wordpress site Developed by Fixing WordPress Problems